Suchergebnisse - "Central nervous system metastases"

PubPharm (101)

1

Osimertinib readministration for central nervous system metastases in non-small cell lung cancer positive for EGFR activating mutations

enthalten in: Respiratory investigation | 2024

von Inutsuka, Y. | Iwama, E. | Shiraishi, Y. | +4

2

Efficacy and survival outcomes of alectinib vs. crizotinib in ALK‑positive NSCLC patients with CNS metastases : A retrospective study

enthalten in: Oncology letters | 2024

von Liu, Q. | Fu, Y. | Guo, J. | +5

3

Latest clinical research in leptomeningeal disease (LMD)-a narrative review

enthalten in: Annals of palliative medicine | 2023

von Chan, A. | Wong, H. | Taphoorn, M. | +13

4

Preclinical and clinical activity of DZD1516, a full blood-brain barrier-penetrant, highly selective HER2 inhibitor

enthalten in: Breast cancer research : BCR | 2023

von Zhang, J. | McAndrew, N. | Wang, X. | +6

5

Preclinical and clinical activity of DZD1516, a full blood–brain barrier-penetrant, highly selective HER2 inhibitor

enthalten in: Breast cancer research | 2023

von Zhang, J. | McAndrew, N. | Wang, X. | +6

6

Preclinical and clinical activity of DZD1516, a full blood–brain barrier-penetrant, highly selective HER2 inhibitor

enthalten in: Breast cancer research | 2023

von Zhang, J. | McAndrew, N. | Wang, X. | +6

7

A study to evaluate the safety, tolerability, processing by the body and effectiveness against BRAF-mutated solid tumours or melanoma of RO7276389 by itself or in combination with cobimetinib : A phase IA/B open-label study to evaluate safety, pharmacokinetics, and preliminary clinical activity of RO7276389 alone and in combination with cobimetinib in participants with Braf-V600 mutation-positive advanced solid tumor or Braf-V600 mutation-positive melanoma with central nervous system metastases

enthalten in: WHO International Clinical Trials Registry Platform | 2023

8

A study to evaluate the safety, tolerability, processing by the body and effectiveness against BRAF-mutated solid tumours or melanoma of RO7276389 by itself or in combination with cobimetinib : A phase IA/B open-label study to evaluate safety, pharmacokinetics, and preliminary clinical activity of RO7276389 alone and in combination with cobimetinib in participants with Braf-V600 mutation-positive advanced solid tumor or Braf-V600 mutation-positive melanoma with central nervous system metastases

enthalten in: WHO International Clinical Trials Registry Platform | 2023

9

Breast Cancer Brain Metastases : Achilles' Heel in Breast Cancer Patients' Care

enthalten in: Cancer treatment and research | 2023

von Ferraro, E. | Seidman, A.

10

Ensartinib in advanced ALK-positive non-small cell lung cancer : a multicenter, open-label, two-staged, phase 1 trial

enthalten in: Journal of thoracic disease | 2022

von Ma, Y. | Pan, H. | Liu, Y. | +13

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[11]